Loading...

APC Annexin V Apoptosis Detection Kit with PI

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5 Apoptosis Detection Kit
Ave. Rating
Submit a Review
Product Citations
publications
APC_Annexin-V_kit_052318
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- APC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (0.03 µg/Test Cat. No. 421301) was added 5 minutes prior to running tubes.
  • APC_Annexin-V_kit_052318
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- APC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (0.03 µg/Test Cat. No. 421301) was added 5 minutes prior to running tubes.
See APC spectral data
Cat # Size Price Quantity Check Availability Save
640932 100 tests 214€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

BioLegend's APC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE/Texas Red® channel with a bandpass filter 610/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.
Application

FC - Quality tested
Recommended Usage

Staining Procedure:
1. Wash cells twice with cold BioLegend's Cell Staining Buffer, and then resuspend cells in Annexin V Binding Buffer at a concentration of 0.25-1.0 x 107 cells/mL.
2. Transfer 100 µL of cell suspension in a 5 mL test tube.
3. Add 5 µL of APC Annexin V.
4. Add 10 µL of Propidium Iodide Solution.
5. Gently vortex the cells and incubate for 15 min at room temperature (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer to each tube. Analyze by flow cytometry with proper machine settings.

Application Notes

Materials Provided:
0.5 ml of APC Annexin V
1 ml of Propidium Iodide Solution
50 ml of Annexin V Binding Buffer

Materials Not Included:
Cell Staining Buffer (Cat. No. 420201)

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Ranganathan P, et al. 2014. J AM Soc Nephrol. 25:239. PubMed
  2. Bernhart E, et al. 2014. Neuro Onco. 16:933. PubMed
Product Citations
  1. Zhou L, et al. 2020. Oxid Med Cell Longev. 2685310:2020. PubMed
  2. Shrestha C,et al. 2017. PLoS One. 10.1371/journal.pone.0186169. PubMed
  3. Ke C, et al. 2022. Cell Biol Int. 46:579. PubMed
  4. Del Rosario RCH, et al. 2022. Nat Microbiol. 7:312. PubMed
  5. Pal D, et al. 2022. Cell Rep Med. 3:100717. PubMed
  6. Gutierrez WR, et al. 2022. JCI Insight. 7: . PubMed
  7. Li W, et al. 2023. Immunol Cell Biol. 101:78. PubMed
  8. Guo F, et al. 2023. Am J Reprod Immunol. 89:e13663. PubMed
  9. Gong Z, et al. 2023. Exp Hematol Oncol. 12:7. PubMed
  10. Gao LT, et al. 2023. Cell Mol Life Sci. 80:58. PubMed
  11. Li X, et al. 2023. J Transl Med. 21:121. PubMed
  12. Bikorimana JP, et al. 2022. iScience. 25:105537. PubMed
  13. Grubb T, et al. 2022. Clin Cancer Res. 28:4689. PubMed
  14. Lampron MC, et al. 2023. Cells. 12:. PubMed
  15. Lee J, et al. 2023. Front Cell Dev Biol. 11:1144110. PubMed
  16. Yakovlev VA, et al. 2023. Front Oncol. 13:1124147. PubMed
  17. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  18. Cui Y, et al. 2023. Research (Wash D C). 6:0162. PubMed
  19. Rodrigues M, et al. 2022. Biochem J. 479:1891. PubMed
  20. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  21. Baldominos P, et al. 2022. STAR Protoc. 3:101795. PubMed
  22. Wang H, et al. 2020. Onco Targets Ther. 13:3903. PubMed
  23. O'Connor CM, et al. 2022. Cancer Res. 82:721. PubMed
  24. Blackburn CMR, et al. 2021. Atherosclerosis. 330:76. PubMed
  25. Azad P, et al. 2022. Exp Mol Med. :. PubMed
  26. Vitali E, et al. 2020. Cancers (Basel). 12:00. PubMed
  27. Daza–Cajigal V, et al. 2019. Front Immunol. 10:2065. PubMed
  28. Cremasco F, et al. 2021. PLoS One. 16:e0241091. PubMed
  29. Wang F, et al. 2021. J Exp Clin Cancer Res. 40:259. PubMed
  30. Sun X, et al. 2022. JCI Insight. 7: . PubMed
  31. Lv ZY, et al. 2022. J Inflamm Res. 15:2819. PubMed
  32. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  33. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  34. Liu K, et al. 2021. Front Cell Dev Biol. 9:678209. PubMed
  35. Zou J, et al. 2015. PLoS One. 10: 0136843. PubMed
  36. Portman N, et al. 2020. Breast Cancer Res. 0.977083333. PubMed
  37. Wang Z, et al. 2017. Elife. 6:e30590. PubMed
  38. Wang J, et al. 2021. Int J Mol Med. 47:643. PubMed
  39. Yetkin D, et al. 2021. EXCLI J. 20:1394. PubMed
  40. Takahashi H, et al. 2019. Sci Rep. 1.136111111. PubMed
  41. Daza-Cajigal V, et al. 2022. Front Immunol. 13:888427. PubMed
  42. Li T, et al. 2021. Front Cell Dev Biol. 9:599020. PubMed
  43. Qi T, et al. 2022. Invest Ophthalmol Vis Sci. 63:11. PubMed
  44. Zhang Y, et al. 2021. Cell Death Discov. 7:192. PubMed
  45. Gomzikova MO, et al. 2020. Sci Rep. 10:10740. PubMed
  46. Nassa G, et al. 2019. Sci Adv. 5:eaav5590. PubMed
  47. Karagül MI, et al. 2020. EXCLI J. 19:532. PubMed
  48. Liu C, et al. 2021. Immun Inflamm Dis. 9:1749. PubMed
  49. Bernhart E, et al. 2014. Neuro Oncology. 16:933. PubMed
  50. Deventhiran J, et al. 2016. J Virol. 90: 222 - 231. PubMed
  51. He L, et al. 2021. Front Physiol. 12:664222. PubMed
  52. Yan Y, et al. 2021. Br J Cancer. 125:101. PubMed
  53. Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed
  54. Quintanal-Villalonga A, et al. 2022. Cancer Res. 82:472. PubMed
  55. Li Y, et al. 2020. Nat Cancer. 1:882. PubMed
  56. Gong Y, et al. 2020. J Neuroinflammation. 0.845833333. PubMed
  57. Zhang S, et al. 2021. Cell Death Discov. 49:7. PubMed
  58. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  59. Lyu X, et al. 2022. Discov Oncol. 13:30. PubMed
  60. Harro CM, et al. 2020. J Clin Invest. . PubMed
  61. Gantenbein N, et al. 2018. Eur J Cancer. 101:165. PubMed
  62. González-Rodríguez P, et al. 2022. Cell Death Dis. 13:953. PubMed
  63. Lohberger B, et al. 2016. PLoS One. 11:e0168193. PubMed
  64. Przystupski D, et al. 2019. Front Pharmacol. 10:851. PubMed
  65. Dudek M, et al. 2021. Nature. 592:444. PubMed
  66. Javellana M, et al. 2022. Cancer Res. 82:169. PubMed
  67. Wang YM, et al. 2022. Oncoimmunology. 11:2034257. PubMed
  68. Surya R, et al. 2016. Carcinogenesis. 37: 635 - 645. PubMed
  69. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
  70. Pogozhykh D, et al. 2017. Stem Cell Res Ther. 10.1186/s13287-017-0512-7. PubMed
  71. Widodo N, et al. 2022. F1000Res. 11:169. PubMed
  72. He S, et al. 2022. Ren Fail. 44:171. PubMed
  73. Baxley RM, et al. 2021. Nat Commun. 1626:12. PubMed
  74. Schnoor B, et al. 2022. Front Bioeng Biotechnol. 10:941817. PubMed
  75. Morretton JP, et al. 2022. EMBO Mol Med. 14:e15670. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Proliferation and Viability, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 3    Revision Date: 11.01.2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account